24.12.2012 Views

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

TPS3637 General Poster Session (Board #39B), Mon, 8:00 AM-12:00 PM<br />

The GAIN-C study (BP25438): Randomized phase II trial <strong>of</strong> RG7160<br />

(GA201) plus FOLFIRI, compared to cetuximab plus FOLFIRI or FOLFIRI<br />

alone in second-line KRAS wild type (WT) or mutant metastatic colorectal<br />

cancer (mCRC). Presenting Author: Andres Cervantes-Ruiperez, Department<br />

<strong>of</strong> Hematology and Medical Oncology, INCLIVA, University <strong>of</strong> Valencia,<br />

Valencia, Spain<br />

Background: GA201 is a novel, dual-acting, humanized, glycoengineered<br />

IgG1 anti-EGFR monoclonal antibody, with enhanced antibody-dependent<br />

cellular cytotoxicity (ADCC) activity in combination with signal inhibition.<br />

GA201 demonstrates significantly enhanced in vitro/vivo activity compared<br />

to cetuximab (cet) both as a single agent and in combination with<br />

irinotecan, in both KRAS mutant and BRAF mutant models and promising<br />

clinical activity in ph I and neo-adjuvant trials (Paz Ares et al, JCO 2011)<br />

including KRAS mutant mCRC. A randomized ph II program was launched:<br />

one study in NSCLC and GAIN-C in mCRC (NCT01326000), which is<br />

presented here. Methods: Main inclusion criteria are progression on 1L<br />

containing oxaliplatin, ECOG 0-1, and adequate hematological and liver<br />

function. Main exclusion criteria: prior anti-EGFR treatment. A total <strong>of</strong> 160<br />

patients in 2L mCRC (stratified for EGFR expression, disease progression<br />

before or after 6 months after starting 1L, prior treatment with bevacizumab<br />

Y vs N) will be randomized to receive either GA201 (day 1, 8 <strong>of</strong> cycle<br />

1 then q2W) or cet (qW) � FOLFIRI q2W (KRAS WT) or to receive GA201�<br />

FOLFIRI or FOLFIRI alone (KRAS mutant). Collection <strong>of</strong> archival tumor<br />

plus a mandatory fresh tumor biopsy at baseline were implemented<br />

because ph I data showed that EGFR expression is not concordant between<br />

the two specimen types and to optimize assessment <strong>of</strong> potential immune<br />

related biomarkers. The fresh tumor biopsy will be centrally analyzed for<br />

EGFR (immunohistochemistry) and KRAS status. Primary objective is<br />

progression free survival; secondary endpoints are to define objective<br />

response rates, the safety pr<strong>of</strong>ile, pharmacokinetics and pharmacodynamics.<br />

A comprehensive biomarker program (blood and tumor), mainly<br />

immune-phenotyping, immunohistochemistry in tumor samples (Ventana)<br />

and immune functional tests (including adaptive responses) were set up to<br />

investigate potential predictive biomarkers and the mode <strong>of</strong> action <strong>of</strong><br />

GA201. Study is ongoing worldwide in 9 countries with the safety run-in<br />

phase completed in Nov 2011. Recruitment is planned to be completed by<br />

end <strong>of</strong> April 2012.<br />

TPS3639 General Poster Session (Board #39D), Mon, 8:00 AM-12:00 PM<br />

Sequential first-line treatment for metastatic colorectal cancer with capecitabine,<br />

irinotecan, and bevacizumab: Capecitabine plus bevacizumab<br />

(Cape-Bev) versus capecitabine, irinotecan plus bevacizumab (CAPIRI-<br />

Bev): The AIO KRK 0110/ML22011 randomized, phase III trial. Presenting<br />

Author: Clemens Albrecht Giessen, Department <strong>of</strong> Hematology and Oncology,<br />

Klinikum Grosshadern and Comprehensive Cancer Center, LMU<br />

Munich, Munich, Germany<br />

Background: Several randomized trials have indicated that combination<br />

chemotherapy applied in metastatic colorectal cancer (mCRC) does not<br />

significantly improve overall survival when compared to the sequential use<br />

<strong>of</strong> cytotoxic agents (CAIRO, MRC Focus, FFCD 2000-05). The present<br />

study investigates the question in bevacizumab-based first-line treatment<br />

including escalation- and de-escalation strategies. Methods: The AIO KRK<br />

0110/ML22011 trial (<strong>Clinical</strong>Trials.gov NCT01249638) is a two-arm,<br />

multicenter, open-label randomized phase III trial comparing the efficacy<br />

and safety <strong>of</strong> Cape-Bev versus CAPIRI-Bev in the first-line treatment <strong>of</strong><br />

metastatic colorectal cancer. Patients with unresectable metastatic colorectal<br />

cancer, ECOG PS 0-1, will be assigned in a 1:1 ratio to receive either<br />

capecitabine 1250 mg/m2 bid for 14d (d1-14) plus bevacizumab 7.5<br />

mg/kg (d1) q3w (Arm A) or capecitabine 800 mg/m2 BID for 14d (d1-14),<br />

irinotecan 200 mg/m2 (d1) and bevacizumab 7.5 mg/kg (d1) q3w (Arm B).<br />

Patients included into this trial are required to consent to the analysis <strong>of</strong><br />

tumor tissue and blood for translational investigations. In Arm A, treatment<br />

escalation from Cape-Bev to CAPIRI-Bev is recommended in case <strong>of</strong><br />

progressive disease (PD). In Arm B, de-escalation from CAPIRI-Bev to<br />

Cape-Bev is possible after 6 months <strong>of</strong> treatment or in case <strong>of</strong> irinotecanassociated<br />

toxicity. Re-escalation to CAPIRI-Bev after PD is possible. The<br />

primary endpoint is time to failure <strong>of</strong> strategy (TFS). Secondary endpoints<br />

are ORR, OS, PFS, safety and quality <strong>of</strong> life. Conclusion: The AIO KRK<br />

0110 trial is designed for patients with disseminated, but asymptomatic<br />

mCRC who are not potential candidates for surgical resection <strong>of</strong> metastasis.<br />

Two bevacizumab-based strategies are compared: one starting as singleagent<br />

chemotherapy (Cape-Bev) allowing escalation to CAPIRI-Bev and<br />

another starting with CAPIRI-Bev and allowing de-escalation to Cape-Bev<br />

and subsequent re-escalation if necessary. By January 2012, 79 <strong>of</strong><br />

planned 516 patients have been enrolled.<br />

Gastrointestinal (Colorectal) Cancer<br />

237s<br />

TPS3638 General Poster Session (Board #39C), Mon, 8:00 AM-12:00 PM<br />

A pilot trial <strong>of</strong> a combination <strong>of</strong> therapeutic vaccines (GI-4000 and<br />

GI-6207) as adjunctive therapy with first-line therapy with bevacizumab<br />

plus either FOLFOX or FOLFIRI in stage IV patients with newly diagnosed<br />

Ras-mutant positive or negative metastatic colorectal cancer. Presenting<br />

Author: John Marshall, Lombardi Comprehensive Cancer Center, Georgetown<br />

University, Washington, DC<br />

Background: A promising approach for the treatment <strong>of</strong> cancer is the<br />

development <strong>of</strong> vaccines that target specific tumor antigens. In the<br />

metastatic CRC patient population, targeted and active immunotherapy<br />

may inhibit cancer progression and improve survival. This trial is designed<br />

to evaluate the efficacy, immunogenicity, and safety <strong>of</strong> GI-4000 plus<br />

standard therapy in patients with metastatic colorectal cancer. GI-4000 is<br />

a proprietary immunotherapy that uses whole, heat-killed recombinant<br />

Saccharomyces cerevisiae yeast (called Tarmogens � Targeted Molecular<br />

Immunogens). GI-4000 is designed to activate a cellular immune response<br />

to target cells with activating ras mutations. Tarmogens have been shown to<br />

elicit selective killing <strong>of</strong> target cells that express a number <strong>of</strong> cancer<br />

antigens, including mutated Ras, by activation <strong>of</strong> antigenspecific T cell<br />

mediated responses. Methods: The study population consists <strong>of</strong> subjects<br />

with metastatic colorectal cancer with an activating mutation in ras. Newly<br />

diagnosed subjects receive FOLFOX (or FOLFIRI) � bevacizumab (Bev) �<br />

GI- 4000; 3 weekly injections <strong>of</strong> GI-4000 are followed by 8 cycles <strong>of</strong> Bev �<br />

FOLFOX (or FOLFIRI); day 1 and 2 every 14 days. Doses <strong>of</strong> GI-4000 are<br />

administered on day 8 <strong>of</strong> each cycle. Upon completion <strong>of</strong> chemotherapy,<br />

GI-4000 continues along with Bev maintenance every 2 weeks for up to 5<br />

years or until subjects experience intolerance, disease recurrence, or death.<br />

If Bev is stopped, GI-4000 may continue on the same maintenance<br />

schedule alone. Subjects that have already completed standard chemotherapy<br />

(FOLFOX or FOLFIRI) may enter the study and receive Bev �<br />

GI-4000 every 2 weeks for up to 5 years. Enrollment is ongoing and will<br />

continue up to 52 subjects.<br />

TPS3640 General Poster Session (Board #39E), Mon, 8:00 AM-12:00 PM<br />

A randomized, phase II, multicenter, double-blind, placebo-controlled<br />

study evaluating onartuzumab (MetMAb) in combination with mFOLFOX6<br />

plus bevacizumab in patients with metastatic colorectal cancer. Presenting<br />

Author: Johanna C. Bendell, Sarah Cannon Research Institute, Nashville,<br />

TN<br />

Background: Dysregulation <strong>of</strong> the HGF/Met (Met) pathway has been linked<br />

with poor prognosis in colorectal cancer. Crosstalk between the Met and<br />

vascular endothelial growth factor (VEGF) pathways may be important<br />

during tumorigenesis. Aberrant activation <strong>of</strong> the HGF/Met pathway may<br />

promote angiogenesis via tumor cell secretion <strong>of</strong> angiogenic factors or<br />

directly activating endothelial cells. Onartuzumab (MetMAb) is a monovalent,<br />

monoclonal antibody that specifically binds to the Met receptor. The<br />

combination <strong>of</strong> onartuzumab and VEGF inhibition in preclinical models<br />

resulted in enhanced antitumor activity over either treatment alone.<br />

Preclinical efficacy data support the combination <strong>of</strong> onartuzumab with<br />

platinum agents. In phase I studies, onartuzumab has been generally well<br />

tolerated alone and in combination with bevacizumab. Adverse events most<br />

commonly associated with onartuzumab are peripheral edema and fatigue.<br />

Methods: This is a randomized, two-arm, phase II study in patients with<br />

previously untreated metastatic colorectal cancer. Patients (n�188) will<br />

be randomized (1:1) to either mFOLFOX6/bevacizumab/placebo or mFOL-<br />

FOX6/bevacizumab/onartuzumab. Oxaliplatin will be discontinued after 8<br />

cycles with remaining drugs continued until progression. The primary<br />

endpoint <strong>of</strong> this study is PFS in all patients. PFS by Met IHC diagnostic<br />

status (Met positive vs Met negative) will also be analyzed. Secondary<br />

endpoints include OS, ORR, safety, and biomarker analyses. Primary and<br />

secondary analyses will include all randomized patients and will be<br />

conducted according to assigned treatment arm. Kaplan–Meier methodology<br />

will be used to estimate median PFS for each treatment arm. An<br />

estimate <strong>of</strong> HR with 95% CI will be determined using a Cox regression<br />

model. Safety will be assessed in all patients receiving at least one dose <strong>of</strong><br />

any treatment. This study is open for accrual; further details can be found<br />

on <strong>Clinical</strong>Trials.gov (NCT01418222).<br />

Visit abstract.asco.org and search by abstract for the full list <strong>of</strong> abstract authors and their disclosure information.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!